Cite
HARVARD Citation
Penson, R. et al. (n.d.). 448TiPMEDIOLA: A phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours – new ovarian cancer cohorts. Annals of oncology. p. . [Online].